advertisement
Abstract #3617 Published in IGR 4-2
Latanoprost and timolol combination therapy versus monotherapy: one-year randomized trial
Higginbotham EJ; Feldman R; Stiles M; DuBiner HArchives of Ophthalmology 2002; 120: 915-922
OBJECTIVE: To compare the efficacy and safety of a fixed combination of 0.005% latanoprost and 0.5% timolol maleate administered once daily versus monotherapy with either 0.005% latanoprost once daily or 0.5% timolol twice daily. METHODS: Patients with either primary or secondary open-angle glaucoma or ocular hypertension participated in a six-month, randomized, double-masked, multicenter study with three parallel treatment groups. The double-masked period was preceded by a two- to four-week 'run-in' treatment with timolol. Subjects could receive fixed combination therapy during a six-month open-label extension. MAIN OUTCOME MEASURE: The difference between groups in mean diurnal intraocular pressure reduction in study eye(s) from baseline through six months of treatment. RESULTS: Overall, 418 patients were enrolled in the study; 332 completed the open-label phase. Diurnal intraocular pressure levels were similar at baseline, but at week 26, they were 19.9 ± 3.4 mmHg in the fixed combination therapy group, 20.8 ± 4.6 mmHg in latanoprost-treated patients, and 23.4 ± 5.4 mmHg in timolol-treated patients (data are given as mean ± SD). The mean change from baseline was greater among patients receiving fixed combination therapy compared with each monotherapy group (p < 0.01). Fixed combination therapy effectively lowered intraocular pressure levels for up to one year. All treatments were well tolerated. CONCLUSION: The combination of 0.005% latanoprost and 0.5% timolol administered once daily is effective and well tolerated for up to 12 months.
Dr. E.J. Higginbotham, Department of Ophthalmology, University of Maryland School of Medicine, 419 W Redwood St, Suite 580, Baltimore, MD 21201, USA. FCWEJH6786@aol.com
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
